Wednesday, June 1, 2016

BRIEF-Eyegate announces data from phase 1B/2A trial of EGP-437

* Majority of subjects treated to-date in two higher dose

cohorts displayed clinically relevant reductions in anterior

chamber cell count (ACC)

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)